The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users.
Shram MJ, Henningfield JE, Apseloff G, Gorodetzky CW, De Martin S, Vocci FL, Sapienza FL, Kosten TR, Huston J, Buchhalter A, Ashworth J, Lanier R, Folli F, Mattarei A, Guidetti C, Comai S, O'Gorman C, Traversa S, Inturrisi CE, Manfredi PL, Pappagallo M.
Shram MJ, et al. Among authors: de martin s.
Transl Psychiatry. 2023 Jun 7;13(1):192. doi: 10.1038/s41398-023-02473-8.
Transl Psychiatry. 2023.
PMID: 37286536
Free PMC article.
Clinical Trial.